A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Status:
Terminated
Trial end date:
2024-04-26
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety of IMG-007 in adults with
moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and
efficacy of IMG-007 in AD patients.